Insights and experience: navigating the diversity and complexity of mRNA-LNP approaches
Mar
19
2024
Upcoming webinar

Insights and experience: navigating the diversity and complexity of mRNA-LNP approaches

Tuesday 08:00 PDT / 11:00 EDT / 15:00 GMT / 16:00 CET
Sponsor
Insights and experience: navigating the diversity and complexity of mRNA-LNP approaches

The COVID-19 pandemic was influential in accelerating the development and evolution of mRNA liquid nanoparticle (mRNA-LNP) technology. The evolution of vaccine technology has increased global demand for manufacturing capacity, allowing governments to prepare for hypothetical outbreaks such as Disease X. Development is not just limited to infectious disease vaccines. Nucleic acid therapeutics can be designed and formulated to silence, express, and edit specific genes, providing a flexible and powerful approach to preventing and treating diseases.

As we step into the next era for mRNA-LNP therapeutics, we will look back on what we learned from our experiences in developing mRNA-LNP research and manufacturing processes in the field. We will also assess the mRNA-LNP workflow in its current form.

Key learnings:

  • The history of mRNA-based therapeutics and their potential in next-generation therapeutics
  • The complexity and diversity of mRNA-LNP approaches, which lead to different challenges for research and manufacturing
  • An overview of mRNA-LNP workflows for research through to manufacturing
  • Insights from in-field experiences and identifying gaps still to be addressed
  • A first look at our new TFF cassette with 100 kDa MWCO, designed for mRNA processes
Dave Sokolowski
Dave Sokolowski
Global Workflow Manager, Nucleic Acid Therapeutics at Cytiva

David is an experienced biopharma professional with many years of industry experience. Dave joined PALL Corporation as an R&D engineer supporting the development of acoustic technologies, before moving into Project Management, and then into Global Product Management. He is an integral part of the cross-functional team between Cytiva, PALL, and PNI, created to design an integrated mRNA workflow.

Prior to his professional career, he acquired a B.S. in Microbiology from the University of Massachusetts, Amherst, which inspired him to join the UMass Med School PhD program investigating the post-transcriptional regulation of mRNA through RNA-binding protein interactions. Prior to completing his PhD, Dave chose to refocus his career towards scientific technology application development, and instead earned a B.S. in Mechanical Engineering from UMass Amherst.

Katarina Stenklo
Katarina Stenklo
Global Product Manager, FlexFactory at Cytiva

Katarina Stenklo holds a licentiate degree in biochemistry and have over 20 years of industry experience. She currently works for Cytiva in the Manufacturing capacity solutions business unit. She has extensive expertise in developing end-to-end manufacturing solutions that includes process workflows, process equipment, automation, consumables, and facilities. Her focus over the last few years has been developing and designing solutions for the manufacture of new product modalities such as viral vectors, plasmids, and mRNA therapies.